AIM OF THE STUDY: A number of observations have indicated that the immune system plays a significant role in patients with epithelial ovarian cancer (EOC). In cases of EOC, the prognostic significance of tumour infiltrating lymphocytes has not been clearly explained yet. The aim is to determine the phenotype and activation molecules of cytotoxic T cell and NK cell subpopulations and to compare their representation in malignant ascites and peripheral blood in patients with ovarian cancer. MATERIAL AND METHODS: Cytotoxic cells taken from blood samples of the cubital vein and malignant ascites were obtained from 53 patients with EOC. Their surface and activation characteristics were determined by means of a flow cytometer. Immunophenotype multiparametric analysis of peripheral blood lymphocytes (PBLs) and tumour infiltrating lymphocytes (TILs) was carried out. RESULTS: CD3(+) T lymphocytes were the main population of TILs (75.9%) and PBLs (70.9%). The number of activating T cells was significantly higher in TILs: CD3(+)/69(+) 6.7% vs. 0.8% (p < 0.001). The representation of (CD3(-)/16(+)56(+)) NK cells in TILs was significantly higher: 11.0% vs. 5.6% (p = 0.041); likewise CD56(bright) and CD-56(bright) from CD56(+) cells were higher in TILs (both p < 0.001). The activation receptor NKG2D was present in 45.1% of TILs vs. 32.3% of PBLs (p = 0.034), but we did not find a significant difference in the numbers of CD56(+)/NKG2D(+) in TILs and PBLs. CONCLUSIONS: These results prove that the characteristics and intensity of anti-tumour responses are different in compared compartments (ascites/PBLs). The knowledge of phenotype and functions of effector cells is the basic precondition for understanding the anti-tumour immune response.

Department of Clinical Immunology and Allergology University Hospital in Hradec Kralove Czech Republic

Department of Medical Biophysics Computer Technology Center; Faculty of Medicine Charles University Prague Hradec Kralove Czech Republic

Department of Obsterics University Hospital in Hradec Kralove; Faculty of Medicine Charles University Prague Hradec Kralove Czech Republic

Department of Oncology and Radiotherapy University Hospital in Hradec Kralove; Faculty of Medicine Charles University Prague Hradec Kralove Czech Republic

Department of Oncology District Hospital Nachod Department of Clinical Microbiology Faculty of Medicine Charles University Prague Hradec Kralove Czech Republic

Department of Oncology District Hospital Nachod Department of Clinical Microbiology Faculty of Medicine Charles University Prague Hradec Kralove Czech Republic ; Department of Dentistry Faculty of Medicine Charles University Prague Hradec Kralove Czech Republic

See more in PubMed

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics 2009. CA Cancer J Clin. 2009;59:225–49. PubMed

Miedzinska-Maciejewska M, Wcislo G, Bodnar L. The modulation of multidrug resistance in ovarian cancer patiens. Współcz Onkol. 2004;8:457–65.

Sikora J. The role of TCRζ expression in immunosuppression induced by tumour. Współcz Onkol. 2009;13:457–65.

Freedman RS, Kudelka AP, Kavanagh JJ, et al. Differential expression of CD3zeta message and protein in tumor infiltrating lymphocytes from solid tumor specimens and malignant ascites from patients with ovarian carcinoma. Clin Cancer Res. 2000;6:2268–78. PubMed

Cózar JM, Canton J, Tallada M, Concha A, Cabrera T, Garrido F, Ruiz-Cabello Osuna F. Analysis of NK cells and chemokine receptors in tumor infiltrating CD4 T lymphocytes in human renal carcinomas. Cancer Immunol Immunother. 2005;54:858–66. PubMed PMC

Gavalas NG, Karadimou A, Dimopoulos MA, Bamias A. Immune Response in Ovarian Cancer: How Is the Immune System Involved in Prognosis and Therapy: Potential for Treatment Utilization. Clin Dev Immunol. 2010;2010:791603. doi: 10.1155/2010/791603. PubMed DOI PMC

Zamarron BF, Chen W. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci. 2011;7:651–8. PubMed PMC

Garrido F, Ruiz-Cabello F, Cabrera T, Pérez-Villar JJ, López-Botet M, Duggan-Keen M, Stern PL. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today. 1997;18:89–95. PubMed

Maleno I, Cabrera CM, Cabrera T, Paco L, López-Nevot MA, Collado A, Ferrón A, Garrido F. Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Immunogenetics. 2004;56:244–53. PubMed

Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol. 2000;74:181–273. PubMed

Ishigami S, Natsugoe S, Tokuda K, et al. Clinical impact of intratumoral natural killer cell and dendritic cell infiltration in gastric cancer. Cancer Lett. 2000;159:103–8. PubMed

Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942–9. PubMed

Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8-tumor-infiltrating lymphocytes and a high CD8-regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102:18538–43. PubMed PMC

Belisle JA, Gubbels JA, Raphael CA, Migneault M, Rancourt C, Connor JP, Patankar MS. Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125) Immunology. 2007;122:418–29. PubMed PMC

Markman M, Markman J, Webster K, Zanotti K, Kulp B, Peterson B, Belinson J. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol. 2004;22:3120–5. PubMed

Kryczek I, Liu R, Wang G, et al. FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res. 2009;69:3995–4000. PubMed

Bamias A, Tsiatas ML, Kafantari E, et al. Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance. Gynecol Oncol. 2007;106:75–81. PubMed

Tsiatas ML, Gyftaki R, Liacos C, Politi E, Rodolakis A, Dimopoulos MA, Bamias A. Study of T lymphocytes infiltrating peritoneal metastases in advanced ovarian cancer: associations with vascular endothelial growth factor levels and prognosis in patients receiving platinum-based chemotherapy. Int J Gynecol Cancer. 2009;19:1329–34. PubMed

Leffers N, Gooden MJ, de Jong RA, et al. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother. 2009;58:449–59. PubMed PMC

Vermeij R, de Bock GH, Leffers N, et al. Tumor-infiltrating cytotoxic T lymphocytes as independent prognostic factor in epithelial ovarian cancer with Wilms tumor protein 1 overexpression. J Immunother. 2011;34:516–23. PubMed

Wakabayashi O, Yamazaki K, Oizumi S, Hommura F, Kinoshita I, Ogura S, Dosaka-Akita H, Nishimura M. CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci. 2003;94:1003–9. PubMed PMC

Kim R, Emi M, Tanabe K. Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity. Immunology. 2006;119:254–64. PubMed PMC

Chen LL, Ye F, Lü WG, Yu Y, Chen HZ, Xie X. Evaluation of immune inhibitory cytokine profiles in epithelial ovarian carcinoma. J Obstet Gynaecol Res. 2009;35:212–8. PubMed

Milliken D, Scotton C, Raju S, Balkwill F, Wilson J. Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites. Clin Cancer Res. 2002;8:1108–14. PubMed

Horalka K, Miyamoto M, Cho Y, et al. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer. 2006;94:275–80. PubMed PMC

Tomšová M, Melichar B, Sedláková I, Steiner I. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol. 2008;108:415–20. PubMed

Girardi M, Glusac E, Filler RB, Roberts SJ, Propperova I, Lewis J, Tigelaar RE, Hayday AC. The distinct contributions of murine T cell receptor(TCR)γδ+ and TCRαβ+ T cells to different stages of chemically induced skin cancer. J Exp Med. 2003;198:747–55. PubMed PMC

Girardi M. Immunosurveillance and Immunoregulation by γδ T Cells. J Invest Dermatol. 2006;126:25–31. PubMed

Ohkawa T, Seki S, Dobashi H, Koike Y, Habu Y, Ami K, Hiraide H, Sekine I. Systematic characterisation of human CD8+ T cells with natural killer cell markers in comparasion with natural cells and normal CD8+ T cells. Imunology. 2001;103:281–90. PubMed PMC

Uhrberg M, Valiante NM, Young NT, Lanier LL, Phillips JH, Parham P. The repertoire of killer cell Ig-like receptor and D94:NKG2A receptors in T cells: Clones sharing identical αβ TcR rearrangement express highly diverse killer cell Ig-like receptor patterns. J Immunol. 2001;166:3923–32. PubMed

Van den Hove LE, Van Gool SW, Vandenberghe P, Boogaerts MA, Ceuppens JL. CD57+/CD28- T cells in untreated hemato-oncological patients are expanded and display a Th1-type cytokine secretion profile, ex vivo cytolytic activity and enhanced tendency to apoptosis. Leukemia. 1998;12:1573–82. PubMed

Kraman M, Bambrough PJ, Arnold JN, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science. 2010;330:827–30. PubMed

Bianchi G, Borgonovo G, Pistoia V, Raffaghello L. Immunosuppressive cells and tumour microenvironment: Focus on mesenchymal stem cells and myeloid derived suppressor cells. Histol Histopathol. 2011;26:941–51. PubMed

Lazennec G, Jorgensen Ch. Concise review: adult multipotent stromal cells and cancer: risk or benefit? Stem Cells. 2008;26:1387–94. PubMed PMC

Miki-Hosokawa T, Hasegawa A, Iwamura C, et al. CD69 controls the pathogenesis of allergic airway inflammation. J Immunol. 2009;183:8203–15. PubMed

Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942–9. PubMed

Wolf D, Wolf AM, Rumpold H, et al. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res. 2005;11:8326–31. PubMed

Wright SE, Rewers-Felkins KA, Quinlin IS, et al. Cytotoxic T-lymphocyte Immunotherapy for ovaria cancor: A pilot study. J Immunother. 2012;35:196–204. PubMed PMC

Linnebacher M. Tumor infiltrating Bcells come into vogue. World J Gastroenterol. 2013;19:8–11. PubMed PMC

Nielsen JS, Sahota RA, Milne K, et al. CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res. 2012;18:3281–92. PubMed

Santin AD, Hermonat PL, Ravaggi A, et al. Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer. Gynecol Obstet Incest. 2001;51:254–61. PubMed

Papamichail M, Perez SA, Gritzapis AD, Baxevanis CN. Natural killer lymphocytes; biology, development and function. Cancer Immunol Immunother. 2004;53:176–86. PubMed PMC

Gubbels JA, Claussen N, Kapur AK, Connor JP, Patankar MS. The detection, treatment, and biology of epithelial ovarian cancer. J Ovarian Res. 2010;29:8. doi: 10.1186/1757-2215-3-8. PubMed DOI PMC

Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, Colonna M, Caligiuri MA. CD56 bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood. 2003;101:3052–7. PubMed

Poli A, Michel T, Thérésine M, Andrès E, Hentges F, Zimmer J. CD56bright natural killer (NK) cells: an important NK cell subset. Imunology. 2009;126:458–65. PubMed PMC

Romagnnani C, Juelke K, Falco M, et al. CD56 bright CD16- killer Ig like receptor – NK cells display longer telomeres and acquire feature of CD56 dim NK cells upon activation. J Immunol. 2007;178:4947–55. PubMed

Patankar MS, Jing Y, Morrison JC, et al. Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA 125. Gynecol Oncol. 2005;99:704–13. PubMed

Jacobs R, Hintzen G, Kemper A, Beul K, Kempf S, Brehrens G, Sykora KW, Schmidt RE. CD56 bright NK cells differ KIR repertoire and cytotoxic features from CD56dim NK cells. Eur J Immunol. 2001;31:3121–6. PubMed

McFarland BJ, Kortemme T, Yu SF, Baker D, Strong RK. Symmetry recognizing asymmetry: analysis of the interactions between the C-type lectin-like immunoreceptor NKG2D and MHC class I-like ligands. Structure. 2003;11:411–22. PubMed

Houchins JP, Yabe T, McSherry C, Bach FH. DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells. J Exp Med. 1991;173:1017–20. PubMed PMC

Gilfillan S, Ho EL, Cella M, Yokoyama WM, Colonna M. NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation. Nat Immunol. 2002;3:1150–5. PubMed

Lanier LL, Corliss BC, Wu J, Leong C, Phillips JH. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature. 1998;391:703–7. PubMed

Garrity D, Call ME, Feng J, Wucherpfennig KW. The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure. Proc Natl Acad Sci U S A. 2005;102:7641–6. PubMed PMC

Champsaur M, Lanier LL. Effect of NKG2D ligand expression on host immune responses. Immunol Rev. 2010;235:267–85. PubMed PMC

Long EO. Negative signaling by inhibitory receptor: the NK cell paradigm. Immunol Rev. 2008;224:70–84. PubMed PMC

Carlsten M, Norell H, Bryceson YT, Poschke I, Schedvins K, Ljunggren HK, Kieslling R, Malmberg KJ. Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK Cells. J Immunol. 2009;183:4921–30. PubMed

Bui JD, Carayannopoulos LN, Lanier LL, Yokoyama WM, Schreiber RD. IFN-dependent down-regulation of the NKG2D ligand H60 on tumors. J Immunol. 2006;176:905–13. PubMed

Barber A, Sentman CL. Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunity. J Immunol. 2009;183:2365–72. PubMed PMC

Barber A, Rynda A, Sentman CL. Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment. J Immunol. 2009;183:6939–47. PubMed PMC